Tests mezigdomide with elranatamab in people with relapsed multiple myeloma
Tests mezigdomide plus elranatamab, to find a safe dose, in adults with relapsed myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Key facts
- Where
- Dresden, Hamburg, and Heidelberg, GermanySee the 3 sites
- Phase
- Phase 1/2
Where in Germany
- Technische Universitaet DresdenDresden, GermanyTaking people
- University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
- Universitaetsklinikum Heidelberg AöRHeidelberg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Celgene
- Trial code
- NCT06988488EU 2025-522090-11-00
- Record updated
- 2 September 2026
- Original description
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).Read full original descriptionShow less
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Inclusion: Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3 prior lines of anti-myeloma therapy (Phase 2); Measurable MM by local laboratory; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1; Adherence to contraception requirements.
Exclusion: Prior treatment with mezigdomide; Prior treatment with T cell engaging or T cell engager (TCE); Prior treatment with B cell-maturation antigen (BCMA)-targeting therapy, with the exception of participants who have received autologous BCMA-targeted CART-cell therapy> 6 months from the start of study therapy; Other protocol-defined Inclusion/Exclusion criteria apply.